HCM
DNA icon

Hollencrest Capital Management’s Ginkgo Bioworks DNA Stock Holding History

Hollencrest Capital Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$743 Hold
75
– – ﹤0.01% 1098
2026
Q1 		$460 Hold
75
– – ﹤0.01% 1125
2025
Q4 		$623 Hold
75
– – ﹤0.01% 1091
2025
Q3 		$1.09K Hold
75
– – ﹤0.01% 1034
2025
Q2 		$844 Hold
75
– – ﹤0.01% 1031
2025
Q1 		$428 Hold
75
– – ﹤0.01% 1062
2024
Q4 		$737 Hold
75
– – ﹤0.01% 1085
2024
Q3 		$611 Hold
75
– – ﹤0.01% 1036
2024
Q2 		$1K Sell
75
-125
-63% -$3.73K ﹤0.01% 984
2024
Q1 		$9.28K Hold
200
– – ﹤0.01% 725
2023
Q4 		$13.5K Hold
200
– – ﹤0.01% 689
2023
Q3 		$14.5K Hold
200
– – ﹤0.01% 676
2023
Q2 		$14.9K Hold
200
– – ﹤0.01% 703
2023
Q1 		$10.6K Hold
200
– – ﹤0.01% 735
2022
Q4 		$13.5K Buy
+200
New +$18.4K ﹤0.01% 678

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Hollencrest Capital Management's DNA Position: Q2 2026 in Review

Hollencrest Capital Management held its Ginkgo Bioworks (DNA) position steady in Q2 2026 at 75 shares worth $743. The position accounts for ﹤0.01% of the portfolio, ranked #1098.

Hollencrest Capital Management first reported a position in DNA in Q4 2022 and has held it in 15 quarters since. The position peaked at $14.9K in Q2 2023. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Hollencrest Capital Management held 75 shares of Ginkgo Bioworks worth $743 as of Q2 2026.
  • Hollencrest Capital Management left its Ginkgo Bioworks share count unchanged in Q2 2026.
  • Ginkgo Bioworks made up ﹤0.01% of Hollencrest Capital Management's portfolio in Q2 2026, its #1098 holding.
  • Hollencrest Capital Management first reported a position in Ginkgo Bioworks in Q4 2022 and has held it in 15 quarters since.
  • Hollencrest Capital Management's Ginkgo Bioworks position peaked at $14.9K in Q2 2023.
  • 184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Hollencrest Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.